A Clinical To Study Evaluate The Effect of Meha Mudgar Rasa in Diabetic Neuropathy

Open Labelled Active Controlled Randomised Evaluation of Meha Mudgara Rasa in the Management of Diabetic Neuropathy - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/04/066544

Enrollment

Registered

2024-04-30

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age between 40 and 75 years (both years inclusive). 2. Both male and female. 3. Known case of Diabetes mellitus with symptoms of Diabetic Neuropathy. 4. Patients with good to moderate glycemic control. 5. Known case of Diabetes mellitus with MNSI Questionnaire score of more than or equal to 7 and MNSI Examination Score of Ã¢â?°Â¥2.5.32 6. Patients showing altered perception of sensory stimulus on the basis of Biothesiometer.

Exclusion criteria

Exclusion criteria: 1. Known case of Rheumatic disease. 2. Known case of Vitamin deficiency. 3. Alcoholism and any other drug abuse. 4. Known case of Paraneoplastic disorder and any other SOL causing nerve dysfunction. 5. Known case of Cerebral vascular disease. 6. Known case of Parkinsonism and any other nerve degenerative disorders. 7. Known case of Leprosy, HIV-AIDS, sexually transmitted disease, and other immune-compromised conditions. 8. Patients with acute complications of Diabetes mellitus. 9. Known case of uncontrolled Hypertension. 10. Patients with known allergy to any drug ingredients of study medicine in trial group and control group

Design outcomes

Primary

Measure	Time frame
Comparison of effect of Meha Mudgara Rasa with Pregabalin in patients of Diabetic neuropathy on the basis of Biothesiometer and Michigan Neuropathy Screening Instrument.Timepoint: Baseline, Day 15, Day 30, day 45, Day 60, Day 75, Day 90	—

Secondary

Measure	Time frame
Compare the efficacy of Meha Mudgara Rasa with Pregabalin in patients of Diabetic neuropathy on the basis of symptoms observed in patientsTimepoint: Baseline, Day 15, Day 30, day 45, Day 60, Day 75, Day 90;Compare the safety of Meha Mudgara Rasa and Pregabalin on the basis of adverse events and biochemical parameters Ã¢â?¬â??haemogram, renal and hepatic function test, urine routine and microscopic and glycosylated hemoglobin.Timepoint: Baseline, Day 90	—

Measure

Time frame

Compare the efficacy of Meha Mudgara Rasa with Pregabalin in patients of Diabetic neuropathy on the basis of symptoms observed in patientsTimepoint: Baseline, Day 15, Day 30, day 45, Day 60, Day 75, Day 90;Compare the safety of Meha Mudgara Rasa and Pregabalin on the basis of adverse events and biochemical parameters Ã¢â?¬â??haemogram, renal and hepatic function test, urine routine and microscopic and glycosylated hemoglobin.Timepoint: Baseline, Day 90

—

Countries

India

Contacts

Public ContactDr Vaishali S Deshpande

Parul Institute of Ayurveda

dr.shaileshd@gmail.com9763104451

Outcome results